KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Equity Average (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Equity Average for 16 consecutive years, with $18.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 14.08% to $18.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 billion, a 14.08% increase, with the full-year FY2025 number at $17.4 billion, up 109.2% from a year prior.
  • Equity Average was $18.5 billion for Q4 2025 at Bristol Myers Squibb, up from $9.4 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $34.6 billion in Q3 2022 to a low of -$19.2 billion in Q1 2023.
  • A 5-year average of $6.0 billion and a median of $1.7 billion in 2022 define the central range for Equity Average.
  • Biggest YoY gain for Equity Average was 5462.5% in 2024; the steepest drop was 500.57% in 2024.
  • Bristol Myers Squibb's Equity Average stood at -$598.5 million in 2021, then skyrocketed by 629.49% to $3.2 billion in 2022, then crashed by 90.79% to $292.0 million in 2023, then skyrocketed by 5462.5% to $16.2 billion in 2024, then rose by 14.08% to $18.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Equity Average are $18.5 billion (Q4 2025), $9.4 billion (Q3 2025), and $175.5 million (Q2 2025).